Research Grade Motavizumab
Product Sizes
1 mg
£506.00
DVV02803-1MG
5 mg
£1169.00
DVV02803-5MG
25 mg
£2865.00
DVV02803-25MG
About this Product
- SKU:
- DVV02803
- Additional Names:
- MEDI-524,NUMAX, NISTmAb, CR9503, CAS: 677010-34-3
- Buffer:
- 0.01M PBS, pH 7.4.
- translate.label.attr.clone:
- Motavizumab
- Clonality:
- Recombinant Monoclonal
- Concentration:
- 2.8 mg/ml
- Extra Details:
- Motavizumab (MEDI-524, NUMAX, NISTmAb) is a second generation monoclonal antibody (mAb) derived from palivizumab (Synagis) using affinity maturation techniques. Motavizumab is currently undergoing US Food and Drug Administration review as a treatment for respiratory syncytial virus (RSV) prophylaxis. It has been evaluated in large-scale clinical studies, and has demonstrated efficacy in reducing the disease burden of RSV in high-risk infant populations.Motavizumab (MEDI-524, NUMAX, NISTmAb) has higher affinity and a longer half-life, was effective in reducing RSV hospitalization in high-risk full-term infants in the US, but was not licensed due to safety concerns (allergic reactions) .
- Host:
- Human
- Immunogen:
- F, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1
- Isotype:
- IgG1, kappa
- Physical State:
- Liquid
- Purity:
- >95%
- Purification:
- Protein A/G purified from cell culture supernatant.
- Reactivities:
- Virus
- Shipping Conditions:
- Blue Ice
- Source:
- XtenCHO
- Storage Conditions:
- -20[o]C Avoid freeze/thaw cycles., 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
- Supplier:
- AntibodySystem
- Type:
- Antibody: Recombinant Antibodies
- Manufacturer's Data Sheet:641.html
